contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-0509-expres2ion-biotechnologies-og-impero

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Equities

Michael Friis

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Impero is a Danish Software-as-a-Service (SaaS) company that provides a compliance management platform. The Impero platform enables companies to easily manage compliance through the automation of risk and control management, documentation, and reporting. Impero empowers companies to become more compliant in a scalable, digital, intuitive, and – most importantly – easy way. Impero is listed at Nasdaq First North in Denmark.

Impero

Dagens aktienyheder med ExpreS2ion Biotechnologies og Impero

ExpreS2ion Biotechnologies offentliggjorde i g&#xe5;r de f&#xf8;rste immunogenicitetsresultater fra deres fase 2 fors&#xf8;g i brystkr&#xe6;ft. Data indikerede, at vaccinen udl&#xf8;ser en markant immunrespons. Dermed en bekr&#xe6;ftelse af, at vaccinen kan aktivere det menneskelige immunsystem, hvilket er den tilsigtede virkningsmekanisme. L&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-first-immunogenicity-confirmation-from-breast-cancer-study?fbclid=IwZXh0bgNhZW0CMTAAYnJpZBEwSWdPc2had0NJV3k4M3FIagEemUzo0t9yV_TgC-Rjmd8sR-SvSnCO9CRez7kSh7g78uqPTJMzF8YqtctleqI_aem_rJzzRxnxwVRCPkbXrzIBvA" target="_blank" rel="noopener">https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-first-immunogenicity-confirmation-from-breast-cancer-study</a>. Du kan ogs&#xe5; l&#xe6;se mere om indregnede sandsynligheder i vores investment case one-pager her: <a href="https://www.inderes.dk/files/f55bb2e1-9b15-4a8b-a8b5-4a60a35c9bfe?fbclid=IwZXh0bgNhZW0CMTAAYnJpZBEwSWdPc2had0NJV3k4M3FIagEeodOiXG7Di28ANSjwlCQcKqWzbTegG3zvTx4Wh-9NJ6iTQrNSW8hKcP9Lpgo_aem_tsWRR6BLFPcJfHzqL5uVmg" target="_blank" rel="noopener">https://www.inderes.dk/files/f55bb2e1-9b15-4a8b-a8b5-4a60a35c9bfe</a>
Impero var i g&#xe5;r repr&#xe6;senteret p&#xe5; et event, hvor selskabets CEO pr&#xe6;senterede resultaterne for H1 2025 og svarede p&#xe5; sp&#xf8;rgsm&#xe5;l fra tilh&#xf8;rerne. I den forbindelse har vi ogs&#xe5; opdateret vores investment case one-pager p&#xe5; selskabet, der kan tilg&#xe5;s og downloades her:&#xa0;<a href="https://www.inderes.dk/research/impero-one-pager-continued-growth-investments-despite-a-challenging-market-in-h1-2025">https://www.inderes.dk/research/impero-one-pager-continued-growth-investments-despite-a-challenging-market-in-h1-2025</a>
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale. /Michael Friis d. 05/09-2025 kl. 09:12.

HC Andersen Capital

<ul>
<li>ExpreS2ion Biotechnologies har offentliggjort positive immunogenicitetsresultater fra deres fase 2 forsøg i brystkræft, hvilket bekræfter, at vaccinen effektivt kan aktivere det menneskelige immunsystem.</li>
<li>Impero deltog i et event, hvor CEO præsenterede resultaterne for første halvår 2025 og besvarede spørgsmål, hvilket har ført til en opdatering af vores investment case one-pager for selskabet.</li>
</ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Dagens aktienyheder 05/09: ExpreS2ion Biotechnologies og Impero

Summary

Stay up to date